Neeraj Agarwal, MD, on Clinical Implications of TITAN Trial Findings on Apalutamide Plus Androgen-Deprivation Therapy for Advanced Prostate Cancer

Posted: Saturday, March 6, 2021

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses what the final results of the TITAN study—improved overall survival and up to a 48% reduction in the risk of death, among other benefits—will mean in clinical practice for patients with metastatic castration-sensitive prostate cancer.